Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312527 | 0.94 | SIGMAR1 (0.71) | SIGMAR1KMT2A | |
| SCHEMBL9350701 | 0.92 | SIGMAR1 (0.72) | SIGMAR1KMT2A | |
| SCHEMBL1148376 | 0.87 | SIGMAR1 (0.68) | SIGMAR1KMT2AMEN1CYP2D6CYP2C9 | |
| SCHEMBL28429716 | 0.84 | SIGMAR1 (0.66) | SIGMAR1KMT2AMEN1CYP2D6CYP2C9 | |
| SCHEMBL18645287 | 0.82 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL22043230 | 0.82 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL19498805 | 0.82 | SIGMAR1 (0.74) | SIGMAR1 | |
| Bromide SCHEMBL6674517 | 0.82 | SIGMAR1 (0.64) | SIGMAR1KMT2AMEN1CYP2D6CYP2C9 | |
| SCHEMBL7022052 | 0.82 | SIGMAR1 (0.64) | SIGMAR1KMT2AMEN1CYP2D6CYP2C19 | |
| SCHEMBL13589884 | 0.82 | SIGMAR1 (1.00) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452774-A | A kind of quick-fried pearl dried orange peel essence and preparation method thereof, quick-fried pearl and cigarette | CHINA TOBACCO HENAN IND CO LTD | 2019-11-15 | — | — | CN | claimed |
| US-5504253-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1996-04-02 | — | — | US | claimed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | claimed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | disclosed |
| US-11224224-B2 | Thiobenzoimidazole as fungicides | REDAG CROP PROTECTION LTD. (GB) | 2022-01-18 | — | — | US | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| CN-1041091-C | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1998-12-09 | — | — | CN | disclosed |
| US-5648540-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| US-5504253-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | SIGMAR1 3967/4885KMT2A 2253/4885MEN1 3132/4885 |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | SIGMAR1 4258/4885KMT2A 4405/4885MEN1 90/4885 |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | SIGMAR1 1640/4885KMT2A 1641/4885MEN1 1528/4885 |
| US-11224224-B2 | Thiobenzoimidazole as fungicides | CYP1B1, CYP51A1, CYP1A2 | SIGMAR1 1784/4885KMT2A 2065/4885MEN1 2482/4885 |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | SIGMAR1 183/4885KMT2A 4361/4885MEN1 3750/4885 |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | TPX2, AIMP2, CDYL2 | SIGMAR1 4507/4885KMT2A 1721/4885MEN1 479/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | SIGMAR1 2970/4885KMT2A 2093/4885MEN1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.